Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Implantable pump could drain fluid for heart failure patients

NCT ID NCT06689553

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tested a device that is surgically placed in the belly to continuously remove extra fluid from the body. It was designed for people with advanced heart failure whose bodies no longer respond to water pills. Only 2 patients were enrolled before the study was stopped, so the results are very limited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
implanted fluid removal device with external pump
What this could lead to
If successful, this device could offer a new way to manage fluid buildup in heart failure patients who no longer respond to standard diuretic medications.
What could go wrong
This is a very early pilot study with only 2 participants, so results may not apply broadly. The device requires surgery to implant, and risks include infection, device malfunction, or complications from the procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

2 people

The number who actually took part.

Started

Sep 2025

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥ 21 years of age * Life expectancy \> 6 months * Heart Failure, New York Heart Association (NYHA) class II-IV * \> 1 HF related admissions in the last 12 months * Fluid congestion (2 signs of pitting oedema, jugular distention, BW elevation, nocturnal dyspnoea score, respiration rate, pulmonary congestion and/or pleural effusion per chest x-ray, ascites) * Failure to achieve effective diuresis and congestion relief despite appropriate or escalating diuretic doses or combination of diuretics * Able to give written informed consent * Ability to comply with study procedures and ability to operate the device themselves or by a regular caregiver support * Residence in proximity to the medical center to ensure easy access for required hospital visits and to enable home visits * Women of childbearing potential should use adequate contraception for as long as the device is implanted Exclusion Criteria: * Any non-cardiac disease with life expectancy \< 1 year * Any patient listed for solid organ transplantation * Patients with a history, or with an indication for mechanical circulatory support * intravenous (IV) inotropes required in last 3 months (INTERMACS Score * 3), excluding Levosimendan * Immunocompromised (e.g. chronic steroid treatment, Human immunodeficiency virus (HIV), etc.) * Insulin dependent diabetes with evidence of infection * Severe hyponatremia as defined by a serum Sodium \< 120 mmol/l * Serum Albumin \< 2.5 g/Dl * Glomerular filtration rate (eGFR) \< 20 ml/min/1.73m2 by MDRD method, using MDRD 4-variable equation that includes age, sex, ethnicity, and serum creatinine * Previous significant intraabdominal surgery, severe abdominal adhesions, intra-abdominal foreign body (except for small inguinal mesh) * Current or historical (within last 6 months) large diaphragmatic hernia, or surgically irreparable, complex or recurring hernia * 6 minutes walk test of less than 100 meters in all repeated testing (if applicable), or similar test * Severe, multiple repeated cardiac-related ascites, subject to principal investigator (PI) discretion * Inflammatory or ischemic bowel disease (i.e., Crohn's disease, ulcerative colitis) and frequent episodes of diverticulitis * Current gastrointestinal active infection in the body (such as Clostridium difficile infection) * Gastrointestinal haemorrhage within the last 4 months * Bacterial peritonitis episode within the last 24 months * \> 2 systemic or local infections, such as urinary tract infection or abdominal skin infection within the last 6 months * Class B or C liver cirrhosis of non-cardiac aetiology * 18.5 \> body mass index (BMI) \> 40 presenting a risk for surgery * Patients with contraindications for general/local anaesthesia, sedation and * or Percutaneous / Laparoscopic surgery * Unsuitability for self-maintenance of the experimental home set-up * Presence of any current cancer, subject to PI discretion * Presence of any active implantable or body-worn devices that cannot be removed excluding Implantable Cardioverter-Defibrillator (ICD) / pacemaker, subject to PI discretion * Known hypersensitivity to Nitinol nickel/titanium alloy and brilliant blue * Pregnancy * Patients being in another therapeutic clinical study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hospital Clínico Universitario de Valencia-España

    Valencia, Spain, 17 46010, Spain

  • University Clinical Centre of Serbia

    Belgrade, Visegradska 26, 11000, Serbia

  • University Clinical Hospital Medical Center "Bezanijska kosa"

    Belgrade, 11080, Serbia

More trials for these conditions

Other studies related to the condition(s) this trial covers.